SVB Leerink analyst Mani Foroohar maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Outperform and lowers the price target from $33 to $30.
Spero Therapeutics Q4 EPS $(0.90) Misses $(0.75) Estimate, Sales $2.74M Miss $4.95M Estimate
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.75) by 20 percent. This is a 32.35 percent decrease over losses of $(0.68) per share from
